HEИндивидуална стипендия2025–2027

MAPiT · Dissolving microneedle array patch-based psoriatic immunotherapy using nanoparticles

„Хоризонт Европа“ — Действия „Мария Склодовска-Кюри“

Период
2025-03-01 → 2027-02-28
Финансиране от ЕС
222 728 €
Участници
2
Схема
HORIZON-TMA-MSCA-PF-EF

Линиите свързват координатора с партньорите.

Накратко на български

Лепенките с разтворими микроигли, заредени с наночастици, които блокират протеина TNF-α, се тестват за лечение на псориазис. Тези методи помагат за по-доброто проникване на лекарството в кожата и намаляват токсичността за целия организъм в сравнение със системните терапии.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Цел на проекта

Psoriasis, an autoimmune disorder characterized by keratinocyte hyperproliferation, predominantly manifests as plaque-type psoriasis, with a majority of cases being mild to moderate. Current treatment approaches, such as topical therapy, often fall short due to limited skin permeability. Systemic drugs and biologics, while effective, pose risks associated with high doses. Addressing mild psoriasis presents the challenge of overcoming limited skin permeability and minimizing systemic drug toxicity. Microneedle Array patches (MAPs) offer a promising alternative. They breach the stratum corneum, facilitating intradermal drug delivery, resulting in higher localized drug concentrations compared to systemic or topical administration. Given the pivotal role of TNF-α in psoriasis, I bring expertise in various MAP fabrication techniques, nanomaterials for drug and mRNA delivery, and their applications. By collaborating with the host, we aim to develop an innovative nanomedicine-based strategy. This approach involves encapsulating TNF-α inhibitors in calcium phosphate nanoparticles using flame spray pyrolysis and loading them into MAPs. The research will encompass various parameters, including size, encapsulation efficiency, release kinetics, mechanical strength, morphology, safety, and in vitro efficacy assessment. Beyond the research project, I will engage in personal development courses, gain exposure to state-of-the-art laboratory facilities, and participate in conferences. Additionally, I will mentor Master's and Ph.D. students, honing my project management skills, and collaborate with industry experts and clinicians to explore the formulation's potential.

Оригинален текст от CORDIS (на английски).

Участници

Връзки

Данни: CORDIS, © Европейски съюз